· Event impact

FDA Extends Review Period for LEQEMBI® IQLIK™ Subcutaneous Injection for Early Alzheimer's

Type: Regulatory ActionConfidence: 1Verified: unverified
The FDA has extended the review period by three months for Eisai and Biogen's supplemental application for LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection, setting a new action date of August 24, 2026, after requesting additional information.

Transmission path

FDA approval timelines directly impact pharmaceutical companies' revenue streams and market access for new drugs.

Extended read

The U.S. Food and Drug Administration (FDA) has announced a three-month extension for the review period of Eisai and Biogen's supplemental Biologics License Application (sBLA) for LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection. This formulation is intended as a starting dose for early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is now set for August 24, 2026. The extension follows the FDA's request for additional information, which constitutes a major amendment to the sBLA. This delay could impact the commercialization timeline and revenue projections for both Eisai and Biogen, as well as the availability of this treatment option for patients.

Exposed assets

BIIB

Countries: US

Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →